Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 3, 2011, Pages 268-278

  Cella, David ^a   Rosenbloom, Sarah K ^a   Beaumont, Jennifer L ^a   Yount, Susan E ^a   Paul, Diane ^b   Hampton, Debra ^b   Abernethy, Amy P ^c   Jacobsen, Paul B ^d   Syrjala, Karen ^e   Von Roenn, Jamie H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b National Comprehensive Cancer Network   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Advanced cancer; Health related quality of life; Measurement; Patient centered; Symptom index

Indexed keywords

ADULT; ADVANCED CANCER; AGED; BLADDER CANCER; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; DIAGNOSTIC VALUE; DRUG EFFICACY; FACT INDEX SCORE; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; NCCN INDEX SCORE; OVARY CANCER; PANCREAS CANCER; PHYSICIAN; PRACTICE GUIDELINE; PROSTATE CANCER; REVIEW; SOCIAL WORK; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION STUDY;

EID: 79952675460     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0026     Document Type: Review

References (37)

1. Guidance for Industry: patient-reported outcome measures: use in medical product development to support labeling claims. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM193282.pdf. Accessed January 20, 2011.
2. Cella DF, Paul D, Yount S, et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 2003;21:526-535. (Pubitemid 37169556)
3. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376. (Pubitemid 23073154)
4. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy (FACT) Scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579. (Pubitemid 23071057)
5. Cella DF, Bonomi AE. Measuring quality of life: 1995 update. Oncology 1995;9(Suppl):47-60.
6. Schag CA, Heinrich RL. Development of a comprehensive quality of life measurement tool: CARES. Oncology (Williston Park) 1990;4:135-138.
7. Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984;2:472-483. (Pubitemid 14075981)
8. Taylor KM, Macdonald KG, Bezak A, et al. Physicians' perspective on quality of life: an exploratory study of oncologists. Qual Life Res 1996;5:5-14. (Pubitemid 26100497)
9. Bezjak A, Taylor KM, Ng P, et al. Quality-of-life information and clinical practice: the oncologist's perspective. Cancer Prev Control 1998;2:230-235. (Pubitemid 29030235)
10. Deyo RA, Patrick DL. Barriers to the use of health status measures in clinical investigation, patient care, and policy research. Med Care 1989;27(Suppl):S254-268.
11. Nelson EC, Berwick DM. The measurement of health status in clinical practice. Med Care 1989;27(Suppl):S77-90.
12. Fish LS, Lewis BE. Quality of life issues in the management of ovarian cancer. Semin Oncol 1999;26(Suppl 1):32-39. (Pubitemid 29093795)
13. Morris J, Perez D, McNoe B. The use of quality of life data in clinical practice. Qual Life Res 1998;7:85-91. (Pubitemid 28113968)
14. Browman GP. Science, language, intuition, and the many meanings of quality of life. J Clin Oncol 1999;17:1651-1653. (Pubitemid 29269232)
15. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994;272:619-626. (Pubitemid 24255222)
16. Guyatt G, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622-629. (Pubitemid 23102698)
17. Hopwood P. Progress, problems, and priorities in quality of life research. Eur J Cancer 1992;28A:1748-1752.
18. Skeel R. Quality of life dimensions that are most important to cancer patients. Oncology 1993;7:55-70.
19. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA 1995;273:59-65.
20. Rothermich EA, Pathak DS. References for health-related quality of life claims in prescription drug advertisements. Am J Health Syst Pharm 1997;43:2596-2599. (Pubitemid 27511869)
21. F-D-C Report: "The Pink Sheet.". Quality of life ad claims should be specific, FDA-sponsored physician focus groups say: ad division direction cautions against QOL "claim expansiveness." 1994;56:8-9.
22. Beitz J. Quality-of-life end points in oncology drug trials. Oncology 1999;13:1439-1447.
23. Quality Of Life Subcommittee of the Oncologic Drugs Advisory Committee, February 10, 2000. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/ohrms/dockets/ac/00/slides/3591s1.htm. Accessed January 20, 2011.
24. Leidy NK, Revicki DA, Genesté B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999;2:113-127.
25. Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994a;3:183-189. (Pubitemid 24253426)
26. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994b;30A:1326-1336. (Pubitemid 24322071)
27. Coons SJ, Kaplan RM. Assessing health-related quality of life: application to drug therapy. Clin Ther 1992;14:850-858. (Pubitemid 23040458)
28. Sutherland HJ, Lockwood GA, Boyd NF. Ratings of the importance of quality of life variables: therapeutic implications for patients with metastatic breast cancer. J Clin Epidemiol 1990;43:661-666. (Pubitemid 20232520)
29. Kong S, Gandhi SK. Methodologic assessments of quality of life measures in clinical trials. Ann Pharmacother 1997;31:830-836. (Pubitemid 27332468)
30. Brunelli C, Costantini M, Di Giulio P, et al. Quality of life evaluation: when do terminal cancer patients and health-care providers agree? J Pain Symptom Manage 1998;15:151-158.
31. Justice AC, Rabeneck L, Hays RD, et al. Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. J AIDS 1999;21:126-133. (Pubitemid 29250076)
32. Nekolaichuk C, Bruera E, Spachynski K, et al. A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat Med 1999;13:311-323. (Pubitemid 29378209)
33. Stephens RJ, Hopwood P, Girling DJ, et al. Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 1997;6:225-236.
34. Stromgren AS, Groenvold M, Sorensen A, et al. Symptom recognition in advanced cancer: a comparison of nursing records against patient self-rating. Acta Anaesthesiol 2001;45:1080-1085. (Pubitemid 32996074)
35. Lampic C, Nordin K, Sjoden P. Agreement between cancer patients and their physicians in the assessment of patient anxiety at followup visits. Psychooncology 1995;4:301-310. (Pubitemid 26094151)
36. Passik SD, Dugan W, McDonald MV, et al. Oncologists' recognitions of depression in their patients with cancer. J Clin Oncol 1998;16:1594-1600. (Pubitemid 28175786)
37. Rao D, Butt Z, Rosenbloom S, et al. A comparison of the Renal Cell Carcinoma Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Pain Symptom Manage 2009;38:291-298.